Phenothiazine compounds of Formula (I) are described herein. These compounds are useful as highly reducing organic photoredox catalysts. Suitable substrates for use with the compounds of Formula (I) include acrylates, styrene, acrylamides, acrylonitrile, vinyl chloride, methylacrylonitrile, vinyl acetate, and acrylic acid.

Phenothiazine compounds of Formula (I) are described herein. These compounds are useful as highly reducing organic photoredox catalysts. Suitable substrates for use with the compounds of Formula (I) include acrylates, styrene, acrylamides, acrylonitrile, vinyl chloride, methylacrylonitrile, vinyl acetate, and acrylic acid.

The present invention is to provide a light emitting material, for an organic EL device, exhibiting higher light emitting efficiency, and particularly, to provide a blue light emitting material, wherein the light emitting material comprises a compound of the following General Formula (1):

##STR00001## X is an aryl group including a tertiary amine structure, and Y is a phenyl group having an alkyl or aryl substituent at one ortho position.

The present invention is to provide a light emitting material, for an organic EL device, exhibiting higher light emitting efficiency, and particularly, to provide a blue light emitting material, wherein the light emitting material comprises a compound of the following General Formula (1):

##STR00001## X is an aryl group including a tertiary amine structure, and Y is a phenyl group having an alkyl or aryl substituent at one ortho position.

The present application relates to an amine compound, which is suitable for use in electronic devices, in particular organic electroluminescent devices (OLEDs). Furthermore, it relates to electronic devices comprising the compound, in particular OLEDs. Furthermore, it relates to a method for synthesizing the above-mentioned amine compound.

The present application relates to an amine compound, which is suitable for use in electronic devices, in particular organic electroluminescent devices (OLEDs). Furthermore, it relates to electronic devices comprising the compound, in particular OLEDs. Furthermore, it relates to a method for synthesizing the above-mentioned amine compound.

The present invention relates to: a process for preparing 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide or chloride; a method of converting 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide to 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride; and the purification of 7-bis-(dimethylamino)-phenothiazin-5-ium chloride by crystallization from aqueous solution of hydrochloric acid, leading to a pharmaceutically acceptable 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride (methylthioninium chloride, methylene blue, MTC) of formula I below reported. ##STR00001##

The present invention relates to a ubiquitin-specific peptidase 24 inhibitor, a medicinal composition including the same and a method of delaying or reversing multidrug resistance in cancers using the same. The USP24 inhibitor, which includes a shUSP24 RNA and/or a carbonyl substituted phenyl compound, can serve as a chemosensitizing agent for inhibiting the drug pump out, cancer sternness and genomic instability of cancer cells, thereby being applied to a medicinal composition and a method for delaying or reversing multidrug resistance in cancers.

The present invention relates to a ubiquitin-specific peptidase 24 inhibitor, a medicinal composition including the same and a method of delaying or reversing multidrug resistance in cancers using the same. The USP24 inhibitor, which includes a shUSP24 RNA and/or a carbonyl substituted phenyl compound, can serve as a chemosensitizing agent for inhibiting the drug pump out, cancer sternness and genomic instability of cancer cells, thereby being applied to a medicinal composition and a method for delaying or reversing multidrug resistance in cancers.

The present invention relates to a ubiquitin-specific peptidase 24 inhibitor, a medicinal composition including the same and a method of delaying or reversing multidrug resistance in cancers using the same. The USP24 inhibitor, which includes a shUSP24 RNA and/or a carbonyl substituted phenyl compound, can serve as a chemosensitizing agent for inhibiting the drug pump out, cancer sternness and genomic instability of cancer cells, thereby being applied to a medicinal composition and a method for delaying or reversing multidrug resistance in cancers.